Colon News and Research

RSS

FDA approves 53 new cancer indications between July 2005 and end of 2007

The U.S. Food and Drug Administration's Office of Oncology Drug Products approved more than 50 new indications for the use of oncology and hematology drugs and biologics between July 2005, when the office began reviewing marketing applications, and the end of 2007, according to a new agency study.

19 Feb 2010

Johns Hopkins Kimmel Cancer Center scientists develop genome-based blood tests for cancer

Scientists at the Johns Hopkins Kimmel Cancer Center have used data from the whole genome sequencing of cancer patients to develop individualized blood tests they believe can help physicians tailor patients' treatments. The genome-based blood tests, believed to be the first of their kind, may be used to monitor tumor levels after therapy and determine cancer recurrence.

19 Feb 2010

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

A signaling protein that is key in orchestrating the body's overall immune response has an important localized role in fighting bacterial infection and inflammation in the intestinal tract, according to a study by UC San Diego School of Medicine investigators, published in the journal Cell Host and Microbe.

18 Feb 2010

Olympus launches new medical devices for LESS surgery

A variety of new medical devices specifically designed for Laparo-Endoscopic Single-Site surgery (LESS surgery) has been announced and introduced by Olympus Europa Holding GmbH and Olympus Medical Systems Corporation. LESS surgery is an advanced, minimally invasive operation technique by which an endoscope and hand instruments are inserted through an access port anchored in just one small incision, usually made in the navel. After developing all the medical devices needed to perform LESS surgery, Olympus has yet again proven its leadership in the field. The release of these innovative devices in Europe took place in autumn 2009.

From Evident Corporation - Life Sciences 18 Feb 2010

Researchers use new strategy to develop cancer vaccines

Researchers at National Jewish Health and the University of Colorado School of Medicine have used a new strategy to develop cancer vaccines that are remarkably effective in mice. In the February 16 issue of the Proceedings of the National Academy of Sciences, Kimberly Jordan, PhD, Jill Slansky, PhD, and John Kappler, PhD, report that 100 percent of the mice vaccinated with a peptide they developed remained alive and tumor-free for at least 60 days after inoculation with colon cancer cells.

17 Feb 2010

Medical journal finds divide between doctors and patients on new mammogram recommendations

News outlets explore confusion about cancer screening guidelines and questions raised about the effects of high tech procedures on health care costs and quality.

17 Feb 2010

Certain patients with IBD at increased risk of developing colorectal cancer: AGA's new guidelines

Certain patients with inflammatory bowel disease (IBD), both ulcerative colitis and Crohn's disease of the colon, have an increased risk of developing colorectal cancer compared to individuals without IBD. A number of factors contribute to the increase in risk, which necessitates an individualized and sensible approach to surveillance in patients, according to a new medical position statement and technical review published by the American Gastroenterological Association in its official journal, Gastroenterology.

17 Feb 2010

Digestive care expert Brenda Watson's website discusses bowel movements and underlying health

Digestive Care Expert Brenda Watson’s new website takes a different look at poop with “The Poop Chronicles,” an eye-opening discussion about what our bowel movements really say about our underlying health. Combining practical information with light-hearted humor, the Poop Chronicles are chock full of digestive wisdom. For example, in the world of healthy poop, size does matter.

16 Feb 2010

Researchers discover Dab2 protein that switches on EMT process

Reporting in Nature Cell Biology, researchers describe the discovery of a specific protein called disabled-2 (Dab2) that switches on the process that releases cancer cells from the original tumor and allows the cells to spread and develop into new tumors in other parts of the body.

15 Feb 2010

New project to unravel secret lives of cancer cells may help produce new cancer therapies

A team of scientists from Princeton University and The Cancer Institute of New Jersey has embarked on a major new project to unravel the secret lives of cancer cells that go dormant and self-cannibalize to survive periods of stress. The work may help produce new cancer therapies to stem changes that render cancer cells dangerous and resistant to treatment.

12 Feb 2010

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.

12 Feb 2010

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Today, Formatech, Inc. announced the issuance of U.S. patent 7,659,310, entitled “Methods of Enhancing Solubility of Agents” which covers novel formulation methods to enhance the solubility of certain hydrophobic compounds.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

HDC signs agreement to receive clinical specimens for colon cancer molecular diagnostic test

Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to provide clinical specimens to be utilized to complete the final validation of HDC's molecular diagnostic test for colon cancer. This test demonstrated a 93% Sensitivity and a 93% Specificity in a previous validation study.

11 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

Biology of lung cancer varies by age and gender

The biology of lung cancer differs from one patient to the next, depending on age and sex, according to scientists at Duke University Medical Center. The findings may help explain why certain groups of patients do better than others, even though they appear to have the same disease.

10 Feb 2010

UnitedHealthcare launches OCA program for cancer patients

UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, launched its Oncology Care Analysis (OCA) program. This patient-focused, integrated program uses a first-of-its-kind database that combines clinical and claims data to gauge the quality of cancer patient care based on approved treatment guidelines from the National Comprehensive Cancer Network (NCCN), an alliance of 21 leading cancer centers.

10 Feb 2010

Seven-day exercise plan for reducing cancer risk

Being active for at least 30 minutes every day reduces your risk of developing some types of cancer. Fitness experts at The University of Texas M. D. Anderson Cancer Center have designed an exclusive exercise plan based on this evidence that will fit into almost anyone's lifestyle.

9 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Colon News and Research

FDA approves 53 new cancer indications between July 2005 and end of 2007

Johns Hopkins Kimmel Cancer Center scientists develop genome-based blood tests for cancer

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

Olympus launches new medical devices for LESS surgery

Researchers use new strategy to develop cancer vaccines

Medical journal finds divide between doctors and patients on new mammogram recommendations

Certain patients with IBD at increased risk of developing colorectal cancer: AGA's new guidelines

Digestive care expert Brenda Watson's website discusses bowel movements and underlying health

Researchers discover Dab2 protein that switches on EMT process

New project to unravel secret lives of cancer cells may help produce new cancer therapies

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Second-quarter fiscal 2010 results announced by Pharmacyclics

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

HDC signs agreement to receive clinical specimens for colon cancer molecular diagnostic test

Medicinal chemistry paper related to the discovery of CUDC-101 published

Biology of lung cancer varies by age and gender

UnitedHealthcare launches OCA program for cancer patients

Seven-day exercise plan for reducing cancer risk

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News